A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.

Snehal G. Patel,David McWilliams,Christine T. Fischette,Jaye Thompson,F. Joseph Daugherty,C. Kent Osborne,Mothaffar F. Rimawi

A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.

2021

Snehal G. Patel
David McWilliams
Christine T. Fischette
Jaye Thompson
F. Joseph Daugherty
C. Kent Osborne
Mothaffar F. Rimawi

TPS604Background: GP2 is a biologic nine amino acid peptide of the HER2/neu protein delivered in combination with an FDA-approved immunoadjuvant Granulocyte-Macrophage Colony Stimulating Factor (GM...

Keywords:

Immunoadjuvant
Pharmacology
HER2/neu
Medicine
Peptide
Breast cancer
Saline
Adjuvant therapy
Trastuzumab
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations